Piribedil (maleate)

Piribedil maleate is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil maleate is also a α2-adrenoceptors antagonist. Piribedil maleate can inhibit MLL1 methyltransferase activity (EC50: 0.18 μM) . Piribedil maleate has the potential for the research of parkinson's disease, circulatory disorders, cancers[1][2][3][4].

Product Specifications

CAS Number

[937719-94-3]

UNSPSC

12352005

Target

Adrenergic Receptor; Dopamine Receptor; Histone Methyltransferase

Type

Reference compound

Related Pathways

Epigenetics; GPCR/G Protein; Neuronal Signaling

Field of Research

Cancer; Endocrinology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/piribedil-maleate.html

Smiles

O=C(/C=C\C(O)=O)O.C1(N2CCN(CC2)CC3=CC=C4OCOC4=C3)=NC=CC=N1

Molecular Formula

C20H22N4O6

Molecular Weight

414.41

References & Citations

[1]Sweet RD, et al. Piribedil, a dopamine agonist, in Parkinson's disease. Clin Pharmacol Ther. 1974 Dec;16 (6) :1077-82. |[2]Gerlach M, et al. The effect of piribedil on L-DOPA-induced dyskinesias in a rat model of Parkinson's disease: differential role of α (2) adrenergic mechanisms. J Neural Transm (Vienna) . 2013 Jan;120 (1) :31-6. |[3]Smith LA, Tet al. Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation. Mov Disord. 2002 Sep;17 (5) :887-901.|[4]Xiong Zhang, et al. Piribedil disrupts the MLL1-WDR5 interaction and sensitizes MLL-rearranged acute myeloid leukemia (AML) to doxorubicin-induced apoptosis. Cancer Lett. 2018 Sep 1;431:150-160.